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Abstract
Background: Tree nut-allergic individuals are often sen-
sitised towards multiple nuts and seeds. The underly-
ing cause behind a multi-sensitisation for cashew nut, 
hazelnut, peanut and birch pollen is not always clear. 
We investigated whether immunoglobulin E antibody 
(IgE) cross-reactivity between cashew nut, hazelnut and 
peanut proteins exists in children who are multi-allergic 
to these foods using a novel IMMULITE®-based inhibition 
methodology, and investigated which allergens might be 
responsible. In addition, we explored if an allergy to birch 
pollen might play a role in this co-sensitisation for cashew 
nut, hazelnut and peanut.
Methods: Serum of five children with a confirmed cashew 
nut allergy and suffering from allergic symptoms after 
eating peanut and hazelnut were subjected to inhibi-
tion immunoassays using the IMMULITE® 2000 XPi. 
Serum-specific IgE (sIgE) to seed storage allergens and 
pathogenesis-related protein 10 (PR10) allergens were 
determined and used for molecular multicomponent aller-
gen correlation analyses with observed clinical symptoms 
and obtained inhibition data.
Results: IgE cross-reactivity was observed in all patients. 
Hazelnut extract was a strong inhibitor of cashew nut sIgE 
(46.8%), while cashew nut extract was less able to inhibit 
hazelnut extract (22.8%). Peanut extract showed the least 
inhibition potency. Moreover, there are strong indications 
that a birch pollen sensitisation to Bet v 1 might play a role 
in the observed symptoms provoked upon ingestion of 
cashew nut and hazelnut.
Conclusions: By applying an adjusted working protocol, 
the IMMULITE® technology can be used to perform inhibi-
tion assays to determine the risk of sIgE cross-reactivity 
between very different food components.
Keywords: allergy diagnostics; cashew nut; hazelnut; IgE 
cross-reactivity; IMMULITE® technology; peanut.
Introduction
Among food allergies, an allergy to tree nuts is rela-
tively common affecting ~0.05–7.3% of the population 
and its prevalence seems to be increasing, especially in 
children [1–3]. The majority of severe food allergy reac-
tions such as anaphylaxis are related to tree nut inges-
tions [4], and tree nut-allergic individuals are often 
sensitised to multiple nuts and seeds [5]. Indeed, in 
the multi-centre Improvement of Diagnostic mEthods 
for ALlergy assessment (IDEAL) study by van der Valk 
et al. [6], co-sensitisation towards peanut and hazelnut 
was observed in more than 60% of Dutch cashew nut-
allergic (multi-sensitised) children, of which 13% (n = 14) 
indicated to also suffer from clinical symptoms upon 
ingestion of all three seeds/nuts (cashew nut, hazelnut 
and peanut). Although cross-sensitisation seems less 
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likely due to low level of botanical relations [7], struc-
tural identity between certain proteins like 2S albumins 
might be possible, and consequently may result in cross-
reactive clinical symptoms. Cashew nut allergies cause 
predominantly severe reactions at very small exposure 
levels [6]. However, all except one child suffered from 
oral allergy syndrome (OAS)-related symptoms next to 
gastrointestinal complaints upon cashew nut ingestion 
and are immunoglobulin E antibody (IgE)-sensitised to 
birch pollen. Five of the 14 multi-allergic children in the 
IDEAL cohort could be selected for further research on 
co- and/or cross-sensitisation patterns to specific aller-
gen components.
Reported co-allergy and IgE cross-reactivity between 
major and minor allergens in hazelnut, peanut and birch 
pollen has been reviewed extensively [3, 8–10]. However, 
an underlying cause that explains a multi-sensitisation to 
cashew nut, hazelnut, peanut and birch pollen has not 
been studied in detail. Thus, our aim in this study was to 
investigate whether IgE cross-reactivity between cashew 
nut, hazelnut and peanut proteins exists in children who 
are multi-allergic to these foods using a novel IMMULITE®-
based inhibition methodology, and which allergens might 
be responsible for the observed IgE cross-reactivity. In 
addition, we explored if an allergy to birch pollen might 
play a role in this co-sensitisation for cashew nut, hazel-
nut and peanut.
Materials and methods
Study design and subjects
Case histories including clinical symptoms after eating hazelnut and 
peanut were collected from the registered electronic patient files and 
questionnaires in the IDEAL study (trial number NTR3572 [11]), as 
well as the result of the double-blind placebo-controlled food chal-
lenge (DBPCFC) with cashew nut, skin prick test (SPT) and IgE data 
specific for whole cashew nut (f220), hazelnut (f17), peanut (f13) and 
birch pollen (t3) [6].
SPT measurements
SPTs against whole nut extracts were performed with cashew nut, 
hazelnut and peanut, a positive control (histamine 10 mg/mL; ALK-
Abello, Nieuwegein, The Netherlands) in duplicate and PBS as a neg-
ative control. The histamine equivalent prick (HEP) index area was 
measured as described previously [11].
Protein extracts for SPTs were obtained from unsalted roasted 
cashew nut and unsalted fresh hazelnut and peanuts (not roasted). 
Seeds were mechanically homogenised using a mortar and pestle, 
defatted by ether extraction and air-dried. A 10% (w/v) extract in 
PBS was centrifuged for 10 min at 2000 g, and the supernatant was 
passed through a 0.22-m filter. All extracts were stored in appropriate 
aliquots at −20 °C until use in the skin test. Before the skin tests, the 
extracts were defrosted and mixed [12].
sIgE-inhibition study
For the IgE-based inhibition tests with cashew nut, hazelnut, pea-
nut and birch pollen, we developed a methodology for specific IgE 
(sIgE)-inhibition testing on the fully automated IMMULITE® 200 XPi 
(see a visual overview in Figure 1). This method is purely experi-
mental without extensive validation and was not performed before. 
For standard routine sIgE quantification, IMMULITE® makes use of 
an enzyme-enhanced chemiluminescent enzyme immunoassay. In 
short, a streptavidin-coated bead, a biotinylated liquid allergen and 
a patient serum sample were mixed and incubated for 30 min. After 
a spin wash, an alkaline phosphatase-conjugated monoclonal anti-
body specific for human IgE (AP-IgE) was added and incubated for 
30 min. After another spin wash, the presence of the AP conjugate 
was measured by adding an AP-specific chemiluminescent substrate 
(phosphate ester of adamantyl dioxetane) which is converted to light. 
The intensity of the light produced is proportional to the amount of 
IgE present in the adjustor.
Allergens for the inhibition steps were prepared from a stock 
solution of nut/seed extract (5  mg/mL) that was provided by Sie-
mens Healthcare Diagnostics (Los Angeles, CA, USA). For the whole 
food-inhibition experiments, a 2% dilution in PBS (100 μg/mL) of the 
allergen stock of choice was used (cashew nut [f202], hazelnut [f17], 
peanut [f13]), while for the Bet v 1-specific inhibitions, a concentra-
tion of 1.6 mg/mL (purified as described in [13]) in PBS was used. The 
nut/seed extracts were produced according to the same procedure as 
the extracts used in the normal IMMULITE® XPi sIgE tests.
Inhibition experiments were performed singly by pre-incubating 
sera with inhibitory allergen preparations mixed 1:1 for 1 h at room 
temperature before proceeding with the normal IMMULITE® XPi sIGE 
testing. Pre-incubations with PBS served as negative controls. The 
percentage of inhibition was calculated using the following formula:
Inhibition serum pre -incubated with PBS serum 
pre -incubated with inhibitor serum 
pre -incubated with PBS
% (
)/
) 100%
= −
×
Allergen sIgE measurements
Serum samples were analysed for sIgE antibodies against cashew 
nut-specific allergens (Ana o 1,2,3) using the Siemens IMMULITE 
2000 XPi® Immunoassay System (Siemens AG, Munich, Germany) 
[14]. Additional sIgE antibodies specific for nCor a 9 and rCor a 
14 were determined using the ImmunoCAP 250 systems. Other sIgE 
measurements for hazelnut (rCor a 1), birch pollen (rBet v 1) and pea-
nut (rAra h 1, rAra h 2, rAra h 3 and rAra h 8) were measured using 
the ImmunoCAP ISAC kit (Thermo Fisher Scientific, Waltham, MA, 
USA). An assay for Cor a 11 was not commercially available. Antibody 
levels above 0.35 kU/L as obtained by IMMULITE® and ImmunoCAP 
250 were considered positive.
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Results
Clinical history
Of the 179 children included in the IDEAL study [6], five 
children with a confirmed DBPCFC test against cashew 
nut plus a positive history of allergic symptoms after 
hazelnut and peanut ingestion were selected for this small 
follow-up study to investigate possible IgE cross- and/or 
co-reactivity between cashew nut, hazelnut and peanut 
allergens. In addition to a clinically relevant food allergy, 
all children suffered from a birch pollen-related inhala-
tion allergy. Baseline characteristics including SPT, whole 
food/pollen-sIgE and case history for cashew nut, hazel-
nut, peanut and birch pollen in the five selected patients 
from the IDEAL study can be found in Table 1.
Inhibition assays
To characterise possible cross-reactive allergens in the 
cashew nut-allergic children, each serum sample was 
exposed to six inhibition tests using biotinylated cashew 
nut, hazelnut and peanut extracts as detection allergens 
and non-biotinylated extracts as inhibitors. First, the 
inhibition of IgE that would be captured by cashew nut 
was investigated. As expected, inhibition of cashew nut-
sIgE with cashew nut protein extract (=positive control) 
reached 90%–99% (Figure 2). Hazelnut, on the other 
hand, was able to inhibit cashew nut-sIgE detection in 
four of the five patients with a mean inhibition rate of 
46.7%. Lowest mean inhibition of cashew nut-sIgE was 
seen for peanut extract (2.6%).
Next, we attempted to inhibit hazelnut-sIgE binding. 
Cashew nut protein extract was able to inhibit hazelnut-
sIgE detection in four of the five patients with a mean of 
24.2%, while peanut was able to inhibit hazelnut-sIgE only 
in patients #1110015 and #3330002 (mean inhibition rate 
5.0%). The positive control extract (hazelnut) was again 
able to inhibit up to 99% of the hazelnut-sIgE.
Peanut-sIgE was inhibited more efficiently by a hazel-
nut than by a cashew nut extract, especially in patient 
#1110063. These results indicate that IgE cross-reactivity 
between cashew nut and hazelnut clearly exists, but the 
role of peanut seems to be negligible.
Allergen-sIgE diagnosis
Hazelnut protein showed to be a strong inhibitor of 
IgE that also specifically binds to cashew nut protein, 
Figure 1: IMMULITE® inhibition methodology.
0. Serum sIgE is pre-incubated with or without an inhibition 
protein extract; 1. Serum and biotinylated capture allergens are 
incubated with streptavidin-coated beads; 2. AP-conjugated anti-IgE 
antibodies are added to the reaction mix; 3. Addition of AP-specific 
substrate results in luminescence that can be quantified. AP, 
alkaline phosphatase.
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especially for patients #1110015 and #2220029. Allergen 
cross-reactivity between nuts might be predominantly 
based on storage proteins [15]. In order to determine for 
each patient whether the albumin- (2S) or globulin-type 
(7S/11S) seed storage allergens might be involved in the 
observed whole food-sIgE-inhibition activity, allergen-
sIgE levels for cashew nut (Ana o 1, Ana o 2 and Ana o 3), 
hazelnut (Cor a 9 and Cor a 14) and peanut (Ara h 1, Ara 
h 2 and Ara h 3) were evaluated (Table 2). As all children 
suffered from a birch pollen inhalation allergy, also sIgE 
levels against the major birch pollen allergen Bet v 1 and 
their equivalents in hazelnut (Cor a 1) and peanut (Ara h 8) 
were measured.
We hypothesise that the relatively strong cashew nut/
hazelnut inhibition observed in patients #1110015 and 
#2220029  might be primarily caused by cross-reactivity 
between globulin allergens Ana o 2 and Cor a 9 rather 
than between 2S albumin allergens. Even though a mean 
inhibition rate of 12.8% was observed of cashew nut-sIgE 
by peanut extract, a peanut-related globulin sensitisation 
seems not to play a role in these two patients, as Ara h 1- 
and Ara h 3-sIgE were both negative. Possibly, a cross-reac-
tivity between the albumin allergens Ana o 3/Ara h 2/Cor 
a 14 may explain the observed peanut-inhibition activity.
Patient #1110063 hardly showed inhibition of cashew 
nut-sIgE with hazelnut and no inhibition of hazelnut-sIgE 
with cashew nut protein extract, even though the serum 
contains sIgE against the 2S and 11S storage protein aller-
gens. On the other hand, peanut-sIgE in this serum was 
strongly inhibited by hazelnut protein extract. Also, this 
serum shows high sIgE levels for the Bet v 1-like allergens 
Cor a 1 and Ara h 8. This suggests that a pathogenesis-
related protein 10 (PR10)-related hazelnut/peanut cross-
reactivity might be a possible cause for the observed 
inhibition (although maybe not clinically relevant as no 
OAS is observed upon peanut ingestion).
The absence of cashew nut-sIgE inhibition by hazel-
nut or peanut was also observed for patient #3330002, 
indicating that cross-reactivity between the 2S albumins 
Ara h 2 and Ana o 3 is unlikely. Also for this patient, a 
PR10-related hazelnut/peanut cross-reactivity might pos-
sibly explain the observed inhibition of hazelnut-sIgE by 
cashew nut (41.2%) and peanut (31.4%) extracts.
Although the positive 2S albumin sensitisation to 
cashew nut (Ana o 3), hazelnut (Cor a 14) and peanut 
(Ara h 2) indicates possible cross-reactivity, neither hazel-
nut- nor cashew nut-sIgE inhibition with peanut extract 
was observed for patient #2220011. This suggests that co-
recognition of allergens in cashew nut and hazelnut by 
peanut 2S albumin-sIgE is unlikely. The observed cashew 
nut/hazelnut inhibition in this patient (72.2% for cashew Ta
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nut-sIgE and 16.7% for hazelnut-sIgE) could also be 
explained by the 11S globulin type of allergens.
Overall, the observed allergen component analysis 
cannot fully explain all cashew nut/hazelnut/peanut-sIgE 
cross-reactivity patterns in the individual patient sera, 
suggesting the involvement of additional allergens in the 
inhibition reactions.
Bet v 1-specific IMMULITE® inhibitions
It was noticed that most patients, except #2220029, dis-
played mild OAS symptoms after consumption of cashew 
nut and hazelnut, next to the more severe gastrointestinal 
complaints. As all children are birch pollen-sensitised, 
we speculated that the observed clinical symptoms as 
Figure 2: IMMULITE sIgE inhibitions by a total cashew nut, hazelnut or peanut protein extract.
(A) Inhibition of cashew nut-sIgE (f202); (B) inhibition of hazelnut-sIgE (f17); (C) inhibition of peanut-sIgE (f13); (D) inhibition of Bet v 1-sIgE (a89).
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well as the measured IMMULITE® sIgE inhibitions in 
some patients might be explained by a secondary (cross-
reactive) reaction on Bet v 1-homologues in cashew nut, 
hazelnut and peanut. Therefore, an inhibition assay with 
nBet v 1 protein was performed on four of the five patients 
(for #3330002 not enough serum was left), as visualised 
in Figure 2D.
Hazelnut-sIgE detection was inhibited in all patients 
with an average of 28.9%, while cashew nut-sIgE was 
only reduced 4.17% in two of the four patients (#1110015 
and #2220011). nBet v 1 hardly captured any peanut-sIgE, 
except in patient #1110063 (2.0%), which might be con-
sistent with the lack of OAS symptoms in these patients 
upon peanut consumption. The Bet v 1-inhibition controls 
in each patient reached over 99% (data not shown). A 
summary of the mean inhibition rates in percentages is 
presented in Figure 3.
Discussion
IgE cross-reactivity generally only occurs between proteins 
belonging to the same allergen family, mostly because of 
structural and sequential similarity [16, 17]. In the studied 
population, only in patients #1110015 and #2220029, a 
strong sIgE cross-reactivity was observed between hazel-
nut and cashew nut protein extracts, which might have 
possibly been caused by a specific 11S globulin sensitisa-
tion. IgE cross-reactivity between the globulin proteins 
Ana o 2 and Cor a 9 has been previously reported by Wal-
lowitz et al. [18]. Also, in vitro cross-reactivity of cashew 
nut, hazelnut and peanut extracts with the walnut 11S 
globulin Jug r 4 has been observed [19].
For patient #2220011, a specific cashew nut/hazel-
nut globulin or albumin cross-reactivity could not be 
distinguished. For a cashew nut and hazelnut allergy, 
Figure 3: Overview of the mean inhibition rates in percentages.
Table 2: sIgE (kU/L) levels of cashew nut, hazelnut, peanut and PR10 birch pollen allergens in the five selected sera, measured by 
ImmunoCAP (CAP), ImmunoCAP ISAC (ISAC) or IMMULITE® (IMM) methodology.
Patient  
 
Cashew nut-sIgE  
 
Hazelnut-sIgE  
 
Peanut-sIgE  
 
Birch 
pollen-sIgE
nAna o 1 
(7S)
  nAna o 2 
(11S)
  nAna o 3 
(2S)
rCor a 1 
(PR10)
  nCor a 9 
(11S)
  rCor a 14 
(2S)
rAra h 1 
(7S)
  rAra h 2 
(2S)
  rAra h 3 
(11S)
  rAra h 8 
(PR10)
rBet v 1 
(PR10)
#1110015   2.4   34.0   10.5   16.8   43.7   0.8   Neg   0.9   Neg   7.8   63.2
#1110063   0.7   2.4   3.9   77.4   0.9   0.4   8.5   6.1   Neg   15.6   119.2
#2220011   Neg   0,9   0.9   8.0   0.5   13.0   Neg   5.7   Neg   15.6   61.3
#2220029   1.9   10.9   16.0   6.8   2.1   Neg   Neg   3.0   Neg   2.47   15.8
#3330002   1.3   5.0   9.2   4.2   Neg   Neg   Neg   3.9   Neg   0.8   14.9
Analysed by   IMM   IMM   IMM   ISAC   CAP   CAP   ISAC   ISAC   ISAC   ISAC   ISAC
2S, 2S albumin; 7S, 7S vicilin; 11S, 11S globulin; PR10, pathogenesis-related protein 10; Neg, negative.
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sensitisation towards the 2S albumins, Ana o 3 and Cor a 
14, respectively, is considered a prediction marker for clin-
ical allergy [14, 20, 21]. However, cross-reactivity between 
these albumins sharing only 43% amino acid identity 
is considered rare [16], although this requires further 
verification.
Peanut displayed the lowest inhibition potency in this 
study. Only one patient (#1110063) was positive for Ara h 
1-sIgE, while none of the patients studied were sensitised 
for the 11S-type globulins, although this could have been 
biased by the low sensitivity of the diagnostics method 
used (ISAC). A predominant 2S albumin sensitisation to 
peanut was detected, as well as a strong sensitisation to 
the birch pollen allergen Bet v 1 and its homologue Ara 
h 8. As none of the patients indicated OAS symptoms 
upon peanut ingestion, the Ara h 8 sensitisation in these 
patients seems to be clinically irrelevant, as also evident 
from the absence of a Bet v 1/peanut-inhibition activity 
in four of the five patients. Perhaps, the Ara h 8-sIgE in 
these patients recognise predominantly conformational 
epitopes that are destroyed upon heating of peanut. 
Although PR10 proteins are heat sensitive, Ara h 8  has 
been suggested as a major allergen in patients with a com-
bined birch pollen and peanut allergy [22, 23]. Unfortu-
nately, a Bet v 1-inhibition test could not be performed for 
patient #3330002 due to serum limitations, while in this 
patient peanut extract was a particular strong inhibitor of 
hazelnut-sIgE.
A 2S albumin sensitisation for peanut is commonly 
associated with severe systemic reactions [24], while from 
the clinical history only mild upper airway symptoms are 
described for three of the five patients. In general, cross-
reactivity between 2S albumins seems to be uncommon 
due to their high amino acid sequence variability [16, 
25], and IgE cross-reactivity of peanut-specific albumins 
occurs primarily between its isotypes rather than with 
tree nut 2S albumins [24, 26]. For instance, peanut did not 
display cross-reactivity with the 2S albumin Jug r 1 from 
walnut [27] nor with 2S albumins from Brazil nut [28], 
which could explain the low peanut-inhibition activity for 
these patients.
On the other hand, peanut-sIgE was inhibited on 
average 12.3 and 34.3% when pre-incubated with cashew 
nut or hazelnut extract, respectively. This contrasts a study 
by de Leon et al. [29], in which no inhibition of peanut-
sIgE by cashew nut was observed, although cross-reactive 
allergen reactivity existed between hazelnut and peanut. 
de Leon et al. [29] applied immobilised peanut extract in 
their inhibition enzyme-linked immunosorbent assays 
(ELISAs) while in the IMMULITE® technique protein con-
formation during inhibition is preserved which possibly 
explains the contrasts observed in inhibition efficiency. 
Why peanut-sIgE can be captured by hazelnut and cashew 
nut while peanut extract displays only weak inhibition 
potency cannot be explained from the allergen multicom-
ponent analysis performed. Possibly, differences in the 
extract’s relative allergen concentrations and/or meas-
urement methods may have interfered in the observed 
varying degrees of inhibitory potency.
Hazelnut and cashew nut extracts were able to 
inhibit the detection of Bet v 1-sIgE in some of the patients 
(#1110015 and #2220011), suggesting that the OAS-related 
symptoms upon ingestion of hazelnut and cashew nut in 
these children could very well be caused by Bet v 1-related 
homologues in both tree nut extracts. A birch pollen/hazel-
nut cross-sensitisation is well known as reviewed by Costa 
et al. [30] and Flinterman et al. [31]; however, evidence for 
a clinically relevant Bet v 1-related cross-reactivity with 
cashew nut is still lacking. Putative IgE-binding homo-
logues of Bet v 1 (PR10) have been identified in cashew 
nut by our group (unpublished results), but whether these 
allergens have cross-reactive potency manifesting in clini-
cal reactions needs further investigation.
The symptoms upon cashew nut or hazelnut inges-
tion could also be caused by a non-PR10-related aller-
gen sensitisation. Allergic reactions towards profilin or 
nsLTP proteins can also result in OAS symptoms [32, 33]. 
However, as none of the patients showed an nsLTP or pro-
filin sensitisation on the ISAC (results not shown), these 
allergens are most likely not involved in the clinical reac-
tions of our five patients.
A limitation in our current study is the use of two differ-
ent specific IgE measurement methods, the ImmunoCAP 
and the ISAC, due to low serum availability. Both methods 
were compared earlier [34, 35] and the detection rates for 
ISAC and ImmunoCAP were comparable: 65% and 71%, 
respectively, in patients with nut allergy. Although the 
detection rates apparently only slightly differ, we cannot 
rule out that this has influence on our results.
In this study, we have successfully demonstrated that 
the IMMULITE® technique can be used to perform IgE-
inhibition assays, as previously also shown for the Immu-
noCAP technique [36]. Although the reproducibility of the 
new method was not tested, the specificity of the inhibi-
tion data measured using this method was demonstrated 
by the strong inhibition obtained by the positive controls. 
The advantage of this technique over the ImmunoCAP 
inhibition technique [36] or the commonly applied immu-
noblot or ELISA-inhibition tests is that inhibition of bioti-
nylated allergens and detection is conducted in the liquid 
form, before conjugation to streptavidin-coated beads 
takes place, meaning that the conformational properties 
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of proteins are conserved, increasing physiological rel-
evance. However, using this method, the minimal amount 
of serum needed per inhibition assay is still substantial 
(90 μL), meaning that no inhibition concentration curves 
could be performed because of serum availability limita-
tions. This prevented us to acquire EC50 values (amount 
of protein extract needed to inhibit 50% of sIgE binding), 
implying that the strength of inhibition or cross-reactive 
potency per protein extract could not be evaluated in 
this study. In addition, available serum levels limited the 
amount of specific allergen inhibitions that could be per-
formed. Globulin-specific inhibitions with Ana o 2 and 
Cor a 9 in particular could have contributed significantly 
to the understanding of sensitisation factors in our study 
population.
From the inhibition data, we could not conclude 
which patients are primarily sensitised to cashew nut 
and secondary to hazelnut or vice versa. As only a small 
sub-population was tested, the patients might be just co-
sensitised and have a primary food allergy for cashew nut, 
hazelnut and birch pollen, and display no secondary food 
allergy. In addition, we are not sure if the possible cross-
reactivity observed in this study is caused by the major 
seed storage allergens, or minor allergens not yet identi-
fied in cashew nut.
Thus, future validation experiments should be per-
formed using larger patient cohorts to compare results 
obtained using the IMMULITE® inhibition technology 
with those obtained using the currently applied inhibition 
ELISA or inhibition ImmunoCAP technologies as well as 
to further validate its reproducibility and applicability in 
allergy diagnostics.
Conclusions
Molecular diagnostic testing by measuring sIgE against 
individual allergen molecules or components using puri-
fied or recombinant allergens (CRD) provides detailed 
information on sensitisation patterns to allergologists and 
enables a more accurate interpretation of allergic symp-
toms by distinguishing clinically relevant food protein 
sensitisation from non-relevant sensitisation that does not 
cause systemic reactions [37]. Moreover, such a CRD anal-
ysis can broaden our understanding of which IgE cross-
reactivity reactions between foods are to be expected in 
a patient group, which may guide dietary advice [3]. We 
have demonstrated that the IMMULITE® technique can 
indeed be applied to evaluate IgE cross-reactivity between 
protein extracts and between specific allergens.
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